AMPE
Income statement / Annual
Last year (2023), Ampio Pharmaceuticals, Inc.'s total revenue was $0.00,
and the percentage change from the previous year is not available.
In 2023, Ampio Pharmaceuticals, Inc.'s net income was -$8.63 M.
See Ampio Pharmaceuticals, Inc.,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
FY-2015
|
FY-2014
|
| Period Ended |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
12/31/2015 |
12/31/2014 |
| Operating Revenue |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$1.16 M |
$76.79 K |
| Cost of Revenue |
$250.00 K
|
$2.08 M
|
$1.09 M
|
$1.18 M
|
$1.27 M
|
$523.00 K
|
$568.00 K
|
$950.00 K
|
$369.31 K
|
$2.24 M
|
| Gross Profit |
-$250.00 K
|
-$2.08 M
|
-$1.09 M
|
-$1.18 M
|
-$1.27 M
|
-$523.00 K
|
-$568.00 K
|
-$950.00 K
|
$793.15 K
|
-$2.16 M
|
| Gross Profit Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0.68
|
-28.18
|
| Research and Development Expenses |
$2.32 M
|
$8.92 M
|
$11.90 M
|
$9.17 M
|
$12.62 M
|
$6.83 M
|
$10.10 M
|
$10.55 M
|
$15.11 M
|
$26.62 M
|
| General & Administrative Expenses |
$7.08 M
|
$11.47 M
|
$8.67 M
|
$6.65 M
|
$5.90 M
|
$4.36 M
|
$5.14 M
|
$6.54 M
|
$9.06 M
|
$8.96 M
|
| Selling & Marketing Expenses |
-$127.00 K
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$3.27 M
|
| Selling, General & Administrative Expenses |
$6.95 M
|
$11.47 M
|
$8.67 M
|
$6.65 M
|
$5.90 M
|
$4.36 M
|
$5.14 M
|
$6.54 M
|
$9.06 M
|
$12.23 M
|
| Other Expenses |
$0.00
|
-$2.08 M
|
-$1.09 M
|
$12.00 K
|
-$1.22 M
|
$0.00
|
$323.55 K
|
$143.80 K
|
$335.79 K
|
$304.42 K
|
| Operating Expenses |
$9.27 M
|
$18.30 M
|
$19.48 M
|
$15.83 M
|
$17.30 M
|
$9.90 M
|
$14.35 M
|
$15.87 M
|
$24.17 M
|
$39.15 M
|
| Cost And Expenses |
$9.52 M
|
$20.38 M
|
$20.57 M
|
$15.83 M
|
$18.58 M
|
$11.18 M
|
$15.57 M
|
$17.08 M
|
$34.47 M
|
$39.15 M
|
| Interest Income |
$348.00 K
|
$220.00 K
|
$4.00 K
|
$12.00 K
|
$77.00 K
|
$5.00 K
|
$3.09 K
|
$23.48 K
|
$59.85 K
|
$22.26 K
|
| Interest Expense |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$77.00 K
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Depreciation & Amortization |
$250.00 K
|
$1.05 M
|
$1.09 M
|
$1.18 M
|
$1.27 M
|
$1.28 M
|
$1.21 M
|
$1.21 M
|
$824.83 K
|
$340.77 K
|
| EBITDA |
-$8.38 M |
-$23.16 M |
-$15.98 M |
-$14.59 M |
-$12.28 M |
$35.26 M |
-$14.46 M |
-$14.81 M |
-$23.34 M |
-$31.11 M |
| EBITDA Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
-20.09
|
-405.11
|
| Operating Income Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
-28.66
|
-409.55
|
| Total Other Income/Expenses Net |
$886.00 K
|
$4.05 M
|
$3.50 M
|
-$60.00 K
|
$4.95 M
|
$45.17 M
|
-$36.22 M
|
-$2.08 M
|
$59.85 K
|
$142.98 K
|
| Income Before Tax |
-$8.63 M
|
-$16.34 M
|
-$17.08 M
|
-$15.89 M
|
-$13.63 M
|
$33.99 M
|
-$51.89 M
|
-$19.16 M
|
-$33.71 M
|
-$39.05 M
|
| Income Before Tax Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
-29.01
|
-508.54
|
| Income Tax Expense |
$0.00
|
-$7.87 M
|
-$4.59 M
|
$604.00 K
|
-$4.95 M
|
$45.17 M
|
$0.00
|
$0.00
|
-$1.29 M
|
-$924.00 K
|
| Net Income |
-$8.63 M
|
-$16.34 M
|
-$17.08 M
|
-$15.89 M
|
-$13.63 M
|
$33.99 M
|
-$51.89 M
|
-$19.16 M
|
-$32.01 M
|
-$38.13 M
|
| Net Income Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
-27.55
|
-496.5
|
| EPS |
-10.67 |
-11.24 |
-18.79 |
-28.63 |
-18.32 |
92.1 |
-239.13 |
-107.06 |
-184.7 |
-228 |
| EPS Diluted |
-10.66 |
-29.32 |
-18.59 |
-27.59 |
-18.32 |
91.9 |
-238.41 |
-106.91 |
-184.7 |
-227.72 |
| Weighted Average Shares Out |
$809.00 K
|
$557.00 K
|
$664.33 K
|
$576.16 K
|
$474.03 K
|
$244.53 K
|
$217.00 K
|
$179.00 K
|
$173.31 K
|
$167.42 K
|
| Weighted Average Shares Out Diluted |
$810.11 K
|
$753.62 K
|
$683.21 K
|
$595.41 K
|
$474.03 K
|
$244.53 K
|
$217.66 K
|
$179.24 K
|
$173.31 K
|
$167.42 K
|
| Link |
|
|
|
|
|
|
|
|
|
|
